AU2014233390B2 - Macrocyclic and bicyclic inhibitors of hepatitis C virus - Google Patents
Macrocyclic and bicyclic inhibitors of hepatitis C virus Download PDFInfo
- Publication number
- AU2014233390B2 AU2014233390B2 AU2014233390A AU2014233390A AU2014233390B2 AU 2014233390 B2 AU2014233390 B2 AU 2014233390B2 AU 2014233390 A AU2014233390 A AU 2014233390A AU 2014233390 A AU2014233390 A AU 2014233390A AU 2014233390 B2 AU2014233390 B2 AU 2014233390B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- optionally substituted
- carbocyclyl
- groups
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/02—Preparation by ring-closure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798961P | 2013-03-15 | 2013-03-15 | |
| US61/798,961 | 2013-03-15 | ||
| PCT/US2014/029765 WO2014145095A1 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic and bicyclic inhibitors of hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014233390A1 AU2014233390A1 (en) | 2015-09-03 |
| AU2014233390B2 true AU2014233390B2 (en) | 2018-03-01 |
Family
ID=50694007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014233390A Active AU2014233390B2 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic and bicyclic inhibitors of hepatitis C virus |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9617310B2 (enExample) |
| EP (1) | EP2970335B1 (enExample) |
| JP (2) | JP6511432B2 (enExample) |
| KR (1) | KR102215400B1 (enExample) |
| CN (1) | CN105073758B (enExample) |
| AU (1) | AU2014233390B2 (enExample) |
| BR (1) | BR112015021768A2 (enExample) |
| CA (1) | CA2902569A1 (enExample) |
| EA (1) | EA029088B1 (enExample) |
| ES (1) | ES2735355T3 (enExample) |
| IL (1) | IL240662A0 (enExample) |
| MX (1) | MX2015013224A (enExample) |
| SG (1) | SG11201507223TA (enExample) |
| WO (1) | WO2014145095A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN105503751B (zh) * | 2015-12-22 | 2018-06-05 | 广西师范大学 | 一种喹喔啉衍生物的高效合成方法 |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| CN111004188B (zh) * | 2019-12-18 | 2021-04-20 | 安徽红杉生物医药科技有限公司 | Ns3/4a蛋白酶抑制剂中间体及其合成方法、应用 |
| CN111018795B (zh) * | 2019-12-25 | 2023-03-28 | 上海彩迩文生化科技有限公司 | 一种碱性条件下合成喹喔啉-3-酮的方法 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010011566A1 (en) * | 2008-07-22 | 2010-01-28 | Merck & Co., Inc. | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0303436A2 (hu) | 2000-12-12 | 2004-01-28 | Schering Corp. | Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| JP5039268B2 (ja) | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| EP1506000B9 (en) | 2002-05-20 | 2011-08-31 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
| US6878722B2 (en) | 2002-05-20 | 2005-04-12 | Bristol-Myers Squibb Company | Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
| WO2004032827A2 (en) | 2002-05-20 | 2004-04-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| SI1615613T1 (sl) | 2003-04-18 | 2010-03-31 | Enanta Pharm Inc | Kinoksalinilni makrociklični inhibitorji serinske proteaze hepatitisa C |
| HRP20080014T3 (en) | 2003-05-21 | 2008-02-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DK1778702T3 (da) | 2004-07-16 | 2011-10-17 | Gilead Sciences Inc | Antivirale forbindelser |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| WO2006119061A2 (en) | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Ｈｃｖ ｎｓ３蛋白酶抑制劑 |
| JP5249028B2 (ja) | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規大環状阻害剤 |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| KR20080036598A (ko) | 2005-08-01 | 2008-04-28 | 머크 앤드 캄파니 인코포레이티드 | Ｈｃｖ ｎｓ３ 프로테아제 억제제로서의 마크로사이클릭펩티드 |
| GEP20104956B (en) | 2005-10-11 | 2010-04-12 | Array Biopharma Inc | Compounds for inhibiting hepatitis c viral replication and use thereof |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| EP2079479B1 (en) | 2006-10-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
| CA2667031C (en) | 2006-10-27 | 2013-01-22 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
| KR20100024920A (ko) | 2007-05-03 | 2010-03-08 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제 |
| MX2009012093A (es) | 2007-05-10 | 2010-01-25 | Intermune Inc | Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c. |
| US20090005387A1 (en) | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| MX2009013827A (es) | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
| MX2009013830A (es) | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| EP2190858A4 (en) | 2007-09-24 | 2013-02-13 | Achillion Pharmaceuticals Inc | PEPTIDES CONTAINING UREA AS INHIBITORS OF VIRAL REPLICATION |
| US8106059B2 (en) | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
| WO2009055335A2 (en) | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| WO2009073719A1 (en) | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl derivatives |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| WO2009082697A1 (en) | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| MX2010008109A (es) | 2008-01-24 | 2010-09-22 | Enanta Pharm Inc | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). |
| KR20100118991A (ko) | 2008-02-04 | 2010-11-08 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 매크로시클릭 세린 프로테아제 억제제 |
| CA2714604A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Macrocyclic hcv ns3 protease inhibitors |
| WO2009114633A1 (en) | 2008-03-12 | 2009-09-17 | Virobay, Inc. | Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives |
| CA2719008A1 (en) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
| KR20110005869A (ko) | 2008-04-15 | 2011-01-19 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제 |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2271345B1 (en) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| WO2009134987A1 (en) | 2008-04-30 | 2009-11-05 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
| KR101647520B1 (ko) | 2008-08-07 | 2016-08-10 | 에프. 호프만-라 로슈 아게 | 거대환식 화합물의 제조 방법 |
| CA2734744A1 (en) | 2008-08-20 | 2010-02-25 | Michael Eissenstat | Hcv protease inhibitors |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| WO2010033466A1 (en) | 2008-09-16 | 2010-03-25 | Phenomix Corporation | Macrocyclic inhibitors of hepatitis c protease |
| AU2009293494B2 (en) | 2008-09-16 | 2014-04-24 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102216321A (zh) | 2008-10-15 | 2011-10-12 | 因特蒙公司 | 治疗性抗病毒肽 |
| WO2010048468A1 (en) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Deuterated macrocyclic inhibitors of viral ns3 protease |
| US8445430B2 (en) | 2008-11-20 | 2013-05-21 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus |
| RS53121B (sr) | 2008-11-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primenu |
| US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| NZ592705A (en) | 2008-12-10 | 2013-02-22 | Achillion Pharmaceuticals Inc | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201034663A (en) | 2008-12-19 | 2010-10-01 | Gilead Sciences Inc | HCV NS3 protease inhibitors |
| BRPI0923393B1 (pt) | 2008-12-23 | 2018-06-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso". |
| CN102458444A (zh) | 2009-05-13 | 2012-05-16 | 英安塔制药有限公司 | 用作丙型肝炎病毒抑制剂的大环化合物 |
| WO2010135748A1 (en) | 2009-05-22 | 2010-11-25 | Sequoia Pharmaceuticals Inc. | Bimacrocyclic hcv ns3 protease inhibitors |
| WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
| CA2770338A1 (en) | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis c virus |
| WO2011038293A1 (en) | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
| WO2011041551A1 (en) | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2011049908A2 (en) | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
| JP5717768B2 (ja) | 2010-03-10 | 2015-05-13 | アッヴィ・バハマズ・リミテッド | 固体組成物 |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| TW201211046A (en) | 2010-06-07 | 2012-03-16 | Enanta Pharm Inc | Macrocyclic hepatitis C serine protease inhibitors |
| WO2012019299A1 (en) | 2010-08-11 | 2012-02-16 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| WO2012037259A1 (en) | 2010-09-15 | 2012-03-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| HUE028384T2 (en) | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| US20130178413A1 (en) | 2010-09-21 | 2013-07-11 | John A. McCauley | Hcv ns3 protease inhibitors |
| US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
| WO2012047764A1 (en) | 2010-10-04 | 2012-04-12 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2012054874A1 (en) | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| EP2635570B1 (en) | 2010-11-01 | 2017-12-13 | RFS Pharma, LLC. | Novel specific hcv ns3 protease inhibitors |
| CA2817365A1 (en) | 2010-12-14 | 2012-06-21 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
| WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6110846B2 (ja) | 2011-05-27 | 2017-04-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
| WO2012176149A1 (en) | 2011-06-23 | 2012-12-27 | Panmed Ltd. | Treatment of hepatitis c virus |
| BR112014003798A2 (pt) | 2011-08-19 | 2017-03-01 | Merck Sharp & Dohme | método para fabricar um composto, e, composto |
| MX2014005210A (es) | 2011-10-31 | 2014-08-22 | Merck Sharp & Dohme | Composiciones utiles para el tratamiento de enfermedades virales. |
| WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| MX2014008205A (es) | 2012-01-12 | 2014-08-08 | Boehringer Ingelheim Int | Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv. |
| UA119315C2 (uk) * | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
-
2014
- 2014-03-14 SG SG11201507223TA patent/SG11201507223TA/en unknown
- 2014-03-14 JP JP2016503218A patent/JP6511432B2/ja active Active
- 2014-03-14 WO PCT/US2014/029765 patent/WO2014145095A1/en not_active Ceased
- 2014-03-14 EA EA201591456A patent/EA029088B1/ru not_active IP Right Cessation
- 2014-03-14 CN CN201480015589.0A patent/CN105073758B/zh active Active
- 2014-03-14 US US14/214,477 patent/US9617310B2/en active Active
- 2014-03-14 AU AU2014233390A patent/AU2014233390B2/en active Active
- 2014-03-14 EP EP14723582.4A patent/EP2970335B1/en active Active
- 2014-03-14 KR KR1020157028437A patent/KR102215400B1/ko active Active
- 2014-03-14 CA CA2902569A patent/CA2902569A1/en not_active Abandoned
- 2014-03-14 BR BR112015021768A patent/BR112015021768A2/pt not_active Application Discontinuation
- 2014-03-14 MX MX2015013224A patent/MX2015013224A/es unknown
- 2014-03-14 ES ES14723582T patent/ES2735355T3/es active Active
-
2015
- 2015-08-18 IL IL240662A patent/IL240662A0/en unknown
-
2017
- 2017-03-10 US US15/455,508 patent/US20170313745A1/en not_active Abandoned
-
2018
- 2018-12-13 JP JP2018233621A patent/JP2019059775A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010011566A1 (en) * | 2008-07-22 | 2010-01-28 | Merck & Co., Inc. | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| IL240662A0 (en) | 2015-10-29 |
| HK1217196A1 (en) | 2016-12-30 |
| SG11201507223TA (en) | 2015-10-29 |
| WO2014145095A1 (en) | 2014-09-18 |
| EA029088B1 (ru) | 2018-02-28 |
| MX2015013224A (es) | 2015-12-11 |
| EP2970335B1 (en) | 2019-05-08 |
| CA2902569A1 (en) | 2014-09-18 |
| US20140274884A1 (en) | 2014-09-18 |
| JP2019059775A (ja) | 2019-04-18 |
| US9617310B2 (en) | 2017-04-11 |
| KR102215400B1 (ko) | 2021-02-10 |
| EP2970335A1 (en) | 2016-01-20 |
| JP6511432B2 (ja) | 2019-05-15 |
| BR112015021768A2 (pt) | 2016-02-02 |
| CN105073758A (zh) | 2015-11-18 |
| CN105073758B (zh) | 2017-08-11 |
| EA201591456A1 (ru) | 2016-02-29 |
| ES2735355T3 (es) | 2019-12-18 |
| US20170313745A1 (en) | 2017-11-02 |
| KR20150130456A (ko) | 2015-11-23 |
| JP2016516069A (ja) | 2016-06-02 |
| AU2014233390A1 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006047A (es) | Degradadores selectivos del receptor de estrogeno. | |
| AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
| AR067475A1 (es) | Antagonistas no basico s del receptor de la hormona concentradora de melanina 1 | |
| PH12018501736A1 (en) | Tetracyclic pyridone compounds as antivirals | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| JP2014514290A5 (enExample) | ||
| HK1203497A1 (en) | Non-systemic tgr5 agonists | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| SI2738156T1 (en) | TETRACYCLINE COMPOSITE SUBSTITUTED WITH 9-AMINOMETHYL | |
| JP2016534037A5 (enExample) | ||
| JP2016501223A5 (enExample) | ||
| JP2011521938A5 (enExample) | ||
| MX2013009709A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7. | |
| RU2015141592A (ru) | АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| JP2016516069A5 (enExample) | ||
| RU2015150120A (ru) | Соединение дикарбоновой кислоты | |
| MX2011013449A (es) | Derivados 774 de 2-carboxamida-7-piperazinil-benzofurano. | |
| PH12016500838A1 (en) | Isoxazolines as therapeutic agents | |
| AR065348A1 (es) | Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer | |
| MX2015013224A (es) | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. | |
| ES2530802T3 (es) | Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos | |
| AR071514A1 (es) | Derivados de aminopiridina | |
| RU2015113959A (ru) | Индолины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |